Hispanic communities, especially in border areas like El Paso, experience disproportionately high rates of liver diseases such as liver fibrosis and non- alcoholic fatty liver disease (NAFLD). These conditions complicate cancer treatment, as liver disease can interfere with drug metabolism, making chemotherapy less effective and increasing harmful side effects. This project aims to understand how liver diseases affect the effectiveness of nanoparticle-based cancer therapies. Nanoparticles are tiny particles used to deliver cancer drugs more effectively by improving solubility, targeting tumors directly, and staying in the bloodstream longer. In patients with liver disease, liver dysfunction may slow the clearance of nanoparticles from the blood, potentially improving their ability to target cancer cells. This research will use animal models to study how liver disease affects the behavior of nanoparticles in both the liver and tumors. The team will also examine how blood proteins from cancer patients with and without liver disease interact with nanoparticles, thereby influencing their ability to deliver treatment to tumors. The goal is to develop better cancer therapies for people with liver disease, particularly in Hispanic populations, improving their chances for successful treatment and a better quality of life.